The company transitioned to a commercial-stage organization following the late December FDA approval of YARTEMLEA, the first and only treatment for TA-TMA.

A strategic asset sale of zaltenibart to Novo Nordisk for up to $2.1 billion provided substantial non-dilutive capital, allowing for the full repayment of senior secured debt.

YARTEMLEA's competitive positioning is driven by its upstream MASP-2 inhibition, which preserves immune function and avoids the 'black box' warnings and REMS programs required for C5/C3 inhibitors.

Management attributes early launch success to pre-approval education efforts, with field forces already detailing centers representing 90% of U.S. allogeneic transplant volume.

The commercial strategy focuses on the 80 highest-volume transplant centers, which account for approximately 80% of the total U.S. market opportunity.

Operational efficiency is supported by a Transition Services Agreement with Novo Nordisk, where Omeros is reimbursed for employee and program costs related to zaltenibart.

Management expects the YARTEMLEA commercial program to be financially self-sustaining within 2026, with a target for total company positive cash flow in 2027.

A regulatory decision from the EMA regarding YARTEMLEA's marketing authorization in Europe is anticipated by mid-year 2026.

The company plans to advance its MASP-2 pipeline, including the Phase II-ready long-acting antibody OMS1029 and a small-molecule program for chronic indications.

Strategic expansion for YARTEMLEA is being evaluated in ARDS and solid organ transplant-related TMA to leverage its endothelial injury mechanism.

Near-term financial milestones from Novo Nordisk totaling $100 million are characterized as 'achievable' and expected to further bolster the balance sheet.

Reported net income was significantly impacted by a $136 million non-cash mark-to-market charge on embedded derivatives, driven by a 319% increase in stock price during Q4.

The company extinguished all senior secured debt and 2026 convertible notes, leaving only $70.8 million in unsecured 2029 notes.

FDA has requested additional preclinical data for the PDE7 inhibitor program (OMS527) before initiating human inpatient studies for cocaine use disorder.

A $17 million non-cash gain was recognized in Q4 related to the derecognition of unamortized premiums following the term loan repayment.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

YARTEMLEA is already on formulary at 50% of the top 10 U.S. transplant centers and 30% of the top 80 centers, exceeding internal expectations.

Early real-world dosing shows a 70/30 split between once-weekly and twice-weekly administration, with a shift toward twice-weekly expected as education increases.

Management noted that lack of formal P&T approval has not prevented hospital sales, as centers are utilizing the drug for urgent patient needs prior to formulary listing.

Third-party payers have approved 100% of pre-authorization requests to date, with many policies already published as 'prior authorization to label.'

The value proposition is framed against the $1 million total cost of a transplant; YARTEMLEA aims to prevent catastrophic outcomes without the infection risks of off-label alternatives.

Omeros plans to publish a formal Health Economics and Outcomes Research (HEOR) analysis soon to further support clinical and economic value claims.

The company is evaluating both broad ex-U.S. partnerships and regional collaborations for YARTEMLEA commercialization outside the United States.

Management declined to provide specific pricing guidance for the EU but emphasized the high unmet need and lack of approved competitors globally.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.